Difference between revisions of "Halothane"
| (6 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
| − | + | {{Unfinished}} | |
| + | |||
'''Halothane''' was one of the most widely used inhalation agents in veterinary patients. However, it has now been overtaken by other agents such as [[Isoflurane|isoflurane]]. It is most commonly used to maintain anaesthesia after induction with an [[Injectable Agents|injectable agent]], although it has also been used to induce anaesthesia when injection is not possible e.g. poor intravenous access. | '''Halothane''' was one of the most widely used inhalation agents in veterinary patients. However, it has now been overtaken by other agents such as [[Isoflurane|isoflurane]]. It is most commonly used to maintain anaesthesia after induction with an [[Injectable Agents|injectable agent]], although it has also been used to induce anaesthesia when injection is not possible e.g. poor intravenous access. | ||
==Pharmacokinetics== | ==Pharmacokinetics== | ||
| − | At room temperature, halothane is a liquid and so requires a [[Vaporisers|vaporiser]] before it reaches the patient. It needs to be stored in a darkened bottle due to ultraviolet degradation. It contains a preservative, Thymol, which can accumulate within the vaporiser The '''blood:gas partition coefficient''' is moderately low meaning that it is relatively insoluble in blood. This results in relatively rapid induction, recovery and depth change. The [[Inhalation | + | At room temperature, halothane is a liquid and so requires a [[Vaporisers|vaporiser]] before it reaches the patient. It needs to be stored in a darkened bottle due to ultraviolet degradation. It contains a preservative, Thymol, which can accumulate within the vaporiser The '''blood:gas partition coefficient''' is moderately low meaning that it is relatively insoluble in blood. This results in relatively rapid induction, recovery and depth change. The [[Inhalation agents#General Pharmacokinetics#Minimum Alevolar Concentration|'''MAC''']] for halothane is approximately ''0.9%'', meaning it is highly potent. Halothane undergoes a degree of hepatic metabolism by the cytochrome P450 system found in hepatocytes. |
==Adverse Effects== | ==Adverse Effects== | ||
| Line 13: | Line 14: | ||
*Decreased cardiac output due to myocardial contraction depression. | *Decreased cardiac output due to myocardial contraction depression. | ||
*Decreased arterial blood pressure. | *Decreased arterial blood pressure. | ||
| − | * | + | *May cause cardiac arrhythmias. |
===Respiratory System=== | ===Respiratory System=== | ||
| Line 25: | Line 26: | ||
==Contraindications== | ==Contraindications== | ||
Halothane should be avoided in patients with increased ICP, cardiac dysfunction, hepatic disease and susceptibility to malignant hyperthermia. | Halothane should be avoided in patients with increased ICP, cardiac dysfunction, hepatic disease and susceptibility to malignant hyperthermia. | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
Revision as of 08:59, 19 April 2009
 |
This article is still under construction. |
Halothane was one of the most widely used inhalation agents in veterinary patients. However, it has now been overtaken by other agents such as isoflurane. It is most commonly used to maintain anaesthesia after induction with an injectable agent, although it has also been used to induce anaesthesia when injection is not possible e.g. poor intravenous access.
Pharmacokinetics
At room temperature, halothane is a liquid and so requires a vaporiser before it reaches the patient. It needs to be stored in a darkened bottle due to ultraviolet degradation. It contains a preservative, Thymol, which can accumulate within the vaporiser The blood:gas partition coefficient is moderately low meaning that it is relatively insoluble in blood. This results in relatively rapid induction, recovery and depth change. The MAC for halothane is approximately 0.9%, meaning it is highly potent. Halothane undergoes a degree of hepatic metabolism by the cytochrome P450 system found in hepatocytes.
Adverse Effects
Central Nervous System
- Causes dose dependent depression but poor analgesic effect.
- Cause cerebral vasodilation but increases intracranial pressure (ICP) therefore should not be used in patients with an increased ICP.
Cardiovascular System
- Decreased cardiac output due to myocardial contraction depression.
- Decreased arterial blood pressure.
- May cause cardiac arrhythmias.
Respiratory System
- Beneficial in patients with increased airway resistance due to bronchodilatory effect.
Other Systems
- Blood flow through the hepatic artery and portal vein are both reduced, which may result in hepatic damage, although unlikely to see clinical signs.
- Reduced renal blood flow and therefore a reduction in glomerular filtration rate.
- Of all the inhalation agents, halothane is the most likely to cause malignant hyperthermia.
Contraindications
Halothane should be avoided in patients with increased ICP, cardiac dysfunction, hepatic disease and susceptibility to malignant hyperthermia.